Search PubMed⌕ Search

Biomedical subjects

A Quinton

Publications and source records attributed to A Quinton.

At least 55 records · Page 3Linked to original sources
PubMed1985

Sinusoids in human cirrhotic nodules: better identification with the perfusion fixation technique.

Liver biopsies of two alcoholic patients with nodular cirrhosis were fixed by perfusion. Sinusoids, sinusoidal cells and the Disse space were well identified in the nodules. Compared to a 'normal' liver biopsy, the following abnormalities were found: a larger Disse space containing fibrillar material and numerous collagen bundles, the extension of the lateral recesses between hepatocytes, the presence of a basement membrane-like material beneath thick and irregular endothelial cells, the transformation of perisinusoidal cells into transitional cells and myofibroblasts-like cells. In addition perisinusoidal processes were clearly identified; they were thick, often containing numerous filaments, and displayed in two or more layers underlined by a discontinuous basement membrane-like material.

Fixatives↗
PubMed1983

Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial.

UNLABELLED: A national multicenter study (34 centers) compared six treatments in 328 patients with cirrhotic ascites. Excluded were patients with g.i. bleeding within the last six months, chronic encephalopathy, cancer, tuberculosis or the following complications persisting after three weeks: acute encephalopythy, fever greater than 38 degrees C, infected ascites or biochemical abnormalities: blood urea greater than 8 mmol/l, natremia less than 130 mmol/l, kaliemia less than 2.5 or greater than 5.5 mmol/l, WBC greater than 12000 mm3, total bilirubin greater than 85.5 mumol/l. In each center patients were randomized into two treatment groups, each center using 2 of 6 proposed treatments: (1) Spironolactone and 500 mg Na p.d (77 patients), (2) Spironolactone + furosemide or Moduretic (amiloride + hydrochlorothiazide) and 500 mg Na p.d (80 patients), (3) Spironolactone + Furosemide or Moduretic and unrestricted sodium diet (86 patients), (4) Concentrated ascites reinfusion and 500 mg Na p.d. (36 patients), (5) Unmodified ascites reinfusion and 500 mg Na p.d. (23 patients), (6) Slow ascites drainage and 500 mg Na p.d. (31 patients). Statistical analysis methods were X2, variance analysis and Spotvoll-Stoline and Dunn-Sidak tests. Before treatment, there was no significant difference between the 6 groups. RESULTS: After one month of treatment, no difference was found in the frequency of total or partial regression of ascites, complications of cirrhosis, mortality, acceptability of treatment. Mechanical treatments induced more rapid weight loss but more frequent recurrence; comparison of groups 2 and 3 did not confirm any benefit associated with unrestricted Na diet. Duration of treatment and hospitalization were shorter in group 4 than in groups 3 and 6.

Amiloride↗
PubMed1983

[Veno-occlusive disease of the liver. Treatment by portocaval shunt].

A case of hepatic veno-occlusive disease revealed by abdominal pains and the rapid constitution of ascites in a 33-year old French female is reported. She had taken medicinal plants in order to loose weight. Liver biopsy showed typical histological changes consisting of centrizonal hemorrhagic necrosis and centrolobular vein obstruction with endophlebitis. Owing to an increase of ascites, a side-to-side portacaval shunt was performed. Eight months postoperatively, ascites had completely disappeared and the liver biopsy showed only a moderate centrolobular vein fibrosis. Five years later, the clinical state is normal.

Adult↗
PubMed1982

[Treatment of cholesterol gallstones with ursodesoxycholic acid (author's transl)].

A double-blind clinical trial comparing ursodesoxycholic acid and chenodesoxycholic acid in patients with cholesterol stones in the gall-bladder showed that ursodesoxycholic acid was superior to the older drug not so much in percentage of biliary calculi dissolved but in dosage reduction (50%) and improved clinical and biological tolerance.

Chenodeoxycholic Acid↗